Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Dermira Inc Market Cap
From what 8 stock analysts predict, the share price for Dermira Inc (DERM) might increase by 78.32% in the next year. This is based on a 12-month average estimation for DERM. Price targets go from $8 to $11. The majority of stock analysts believe DERM is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 8 Wall Street analysts have assignedDERM 7 buy ratings, 0 hold ratings, and 1 sell ratings. This means that analysts expect Dermira Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on DERM. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of DERM.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Thomas Flaten Lake Street | Buy | $9 | Initiates | Sep 6, 2024 |
Rodman & Renshaw | Buy | $9 | Initiates | Aug 22, 2024 |
| Jason Wittes Roth MKM | Buy | $11 | Reinstates | Jun 28, 2024 |
| Scott Henry Alliance Global Partners | Buy | $8.5 | Initiates | Feb 16, 2024 |
| Kalpit Patel B. Riley Securities | Buy | $6 | Reiterates | Sep 7, 2023 |
| Kalpit Patel B. Riley Securities | Buy | $6 | Maintains | Jul 12, 2023 |
| Kalpit Patel B. Riley Securities | Buy | $3 | Maintains | May 23, 2023 |
| Kalpit Patel B. Riley Securities | Buy | $6 | Reiterates | Mar 30, 2023 |
| Brandon Folkes Cantor Fitzgerald | Overweight | $9 | Initiates | Feb 25, 2022 |
Roth Capital | Buy | Initiates | Dec 16, 2021 | |
B. Riley Securities | Buy | Initiates | Dec 7, 2021 | |
Mizuho | Buy | $14 | Upgrade | Jun 6, 2019 |
| Irina Rivkind Koffler Mizuho | Neutral | $9 | Downgrade | Mar 6, 2018 |
Citigroup | Buy | $40 | Maintains | Mar 16, 2016 |
Citigroup | Buy | $42 | Upgrade | Dec 18, 2015 |
Needham | Buy | $33 | Maintains | Aug 17, 2015 |
Leerink Swann | Outperform | $34 | Maintains | Mar 26, 2015 |
When did it IPO
2021
Staff Count
41
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers—Specialty & Generic
CEO
Mr. Claude Maraoui
Market Cap
$106.1M
In 2023, DERM generated $79.2M in revenue, which was a increase of 7.48% from the previous year. This can be seen as a signal that DERM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 12 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Journey Medical Corporation (NASDAQ:DERM ) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - Chief Financial Officer Srini Sidgiddi - Vice President, Research and Development Ramsey Alloush - General Counsel and Corporate Secretary Conference Call Participants Kalpit Patel - B. Riley Securities Scott Henry - Alliance Global Partners Jason Wittes - Roth Operator Ladies and gentlemen, thank you for standing by.
Mon, 12 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Journey Medical Corporation (DERM) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.46 per share a year ago.
Mon, 12 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase from the $13.0 million reported in the first quarter of 2024 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz.
Tue, 06 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Company to host conference call to discuss financial results and provide a corporate update on August 12, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on August 12, 2024 at 4:30 p.m. ET
Thu, 11 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors.
Wed, 15 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, announced today that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase on Tuesday, May 21, 2024, at 1:00 p.m. ET.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
